# SGR-1505

Source: https://onco.cc/drugs/sgr-1505/  
OnCo record `sgr-1505` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SGR-1505 is an experimental small molecule from Schrödinger, in phase 1 trials for relapsed or refractory B-cell malignancies, waldenström macroglobulinaemia and chronic lymphocytic leukaemia and other cancers.

## Summary

SGR-1505 is a small molecule (oral) from Schrödinger. An inhibitor of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1), which the company describes as a key mediator of the NF-κB signalling pathway and the main driver of a subset of B-cell lymphomas. Its furthest stage is phase 1, for relapsed or refractory B-cell malignancies, waldenström macroglobulinaemia, chronic lymphocytic leukaemia and non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. 10-Q for the quarter to 30 June 2026 (filed 5 August 2026): Schrödinger will complete the ongoing phase 1 dose-escalation trial, does not intend to start further trials independently, and plans to seek strategic partners. FDA Fast Track (June 2025) for relapsed/refractory Waldenström macroglobulinaemia after at least two lines including a BTK inhibitor. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: SGR-1505
- Modality: Small molecule (oral)
- Mechanism: An inhibitor of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1), which the company describes as a key mediator of the NF-κB signalling pathway and the main driver of a subset of B-cell lymphomas.

## Sources

- Schrödinger: schrodinger.com: https://www.schrodinger.com/pipeline/
- Schrödinger: sec.gov: https://www.sec.gov/Archives/edgar/data/1490978/000149097825000099/sdgr-20250630xexx991.htm
- Schrödinger: sec.gov: https://www.sec.gov/Archives/edgar/data/1490978/000149097825000099/sdgr-20250630xexx991.htm
- Schrödinger: sec.gov: https://www.sec.gov/Archives/edgar/data/1490978/000149097826000068/sdgr-20260630.htm
- ClinicalTrials.gov: trials of SGR-1505: https://clinicaltrials.gov/search?intr=SGR-1505

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- targets: [MALT1](https://onco.cc/targets/malt1/)
- companies: [Schrödinger](https://onco.cc/companies/schrodinger/)
- trials: [Study of SGR-1505 in Mature B-Cell Neoplasms](https://onco.cc/trials/nct05544019/)

---
JSON: https://onco.cc/api/v1/entities/sgr-1505.json